Search Results

You are looking at 1 - 2 of 2 items for

  • Author or Editor: Dina A. Andrews x
  • Refine by Access: All Content x
Clear All Modify Search


Objective—To evaluate antiplatelet effects and pharmacodynamics of clopidogrel in cats.

Design—Original study.

Animals—5 purpose-bred domestic cats.

Procedure—Clopidogrel was administered at dosages of 75 mg, PO, every 24 hours for 10 days; 37.5 mg, PO, every 24 hours for 10 days; and 18.75 mg, PO, every 24 hours for 7 days. In all cats, treatments were administered in this order, with at least 2 weeks between treatments. Platelet aggregation in response to ADP and collagen and oral mucosal bleeding times (OMBTs) were measured before and 3, 7, and 10 days (75 and 37.5 mg) or 7 days (18.75 mg) after initiation of drug administration. Serotonin concentration in plasma following stimulation of platelets with ADP or collagen was measured before and on the last day of drug administration. Platelet aggregation, OMBT, and serotonin concentration were evaluated at various times after drug administration was discontinued to determine when drug effects were lost.

Results—For all 3 dosages, platelet aggregation in response to ADP, platelet aggregation in response to collagen, and serotonin concentration were significantly reduced and OMBT was significantly increased at all measurement times during drug administration periods. All values returned to baseline values by 7 days after drug administration was discontinued. No significant differences were identified between doses. None of the cats developed adverse effects associated with drug administration.

Conclusions and Clinical Relevance—Results suggest that administration of clopidogrel at dosages ranging from 18.75 to 75 mg, PO, every 24 hours, results in significant antiplatelet effects in cats. (J Am Vet Med Assoc 2004;225:1406–1411)

Full access
in Journal of the American Veterinary Medical Association


Objective—To determine whether ticlopidine exerts an antiplatelet effect, estimate the pharmacodynamics of ticlopidine, and evaluate any acute adverse effects associated with administration of ticlopidine in cats.

Animals—8 domestic purpose-bred sexually intact male cats.

Procedure—Ticlopidine was administered orally (50 mg, q 24 h; 100 mg, q 24 h; 200 mg, q 24 h; and 250 mg, q 12 h). Each treatment period consisted of 10 days of drug administration. Platelet aggregation studies with adenosine diphosphate (ADP) and collagen and evaluation of oral mucosal bleeding times (OMBTs) were performed on days 3, 7, and 10 during each drug administration. Serotonin was measured to evaluate secretion at baseline and on day 10 for cats that received the 250-mg dosage.

Results—A significant reduction in platelet aggregation was detected in response to ADP on days 7 and 10 at 100 mg, on day 3 at 200 mg, and on days 3, 7, and 10 at 250 mg. A significant increase in the OMBT and decrease in serotonin release on day 10 at 250 mg was also detected; however, the cats had anorexia and vomiting at the 250-mg dosage.

Conclusions and Clinical Relevance—Although there was a consistent antiplatelet effect at the 250-mg dosage, there was dose-dependent anorexia and vomiting that we conclude precludes the clinical usefulness of this drug in cats. ( Am J Vet Res 2004;65:327–332)

Full access
in American Journal of Veterinary Research